Table 1.
Demographic and clinical information.
| Sz | HCSz | p | FESz | HCFE | p | |
|---|---|---|---|---|---|---|
| Age | 35.1 (7.9) | 34.9 (10.4) | 0.91 | 23.0 (4.7) | 23.6 (4.6) | 0.56 |
| Gender (M/F) | 33/17 | 32/18 | 0.83 | 30/10 | 28/12 | 0.62 |
| SES | 32.0 (13.1) | 44.4 (11.1) | <.001 | 30.4 (12.5) | 37.3 (10.2) | 0.009 |
| Parental SES | 37.3 (14.4) | 40.3 (11.6) | 0.25 | 41.2 (13.4) | 45.9 (12.5) | 0.11 |
| PANSS Total | 68.2 (12.8) | 75.4 (15.2) | ||||
| PANSS Positive | 15.2 (5.0) | 20.1 (5.4) | ||||
| PANSS Negative | 18.7 (5.4) | 17.1 (5.0) | ||||
| PANSS General | 34.3 (5.7) | 38.2 (8.3) | ||||
| PANSS TD | 8.3 (3.0) | 11.3 (3.2) | ||||
| SAPS Global | 4.0 (2.9) | 6.5 (3.5) | ||||
| SANS Global | 11.8 (3.2) | 9.4 (4.2) | ||||
| Illness duration | 12.2 (7.4)a | 17.2 (21.2)b | ||||
| DUP | – | 1.6 (2.5) | ||||
| Medication | 783.3 (1273.4) | 269.7 (336.9) |
Values are mean (SD). Age in years. Illness duration in years. SES, Socio-Economic Status; PANSS, Positive and Negative Syndrome Scale; SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; Illness duration, time since first hospitalization or first contact with psychiatric services; ayears ill, bdays ill. DUP, Duration of untreated psychosis in years. Medication in chlorpromazine equivalents [oral dosages from Andreasen et al., 2010 (35), depot dosages from Gardner et al., 2010 (36)]. Bolded means statistically significantly different